Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in studies of small-animal models involving challenge by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 in treatment of nonhuman primates infected with variola virus or monkeypox virus was assessed. The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival.
U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.
John
J
Huggins
Arthur
A
Goff
Lisa
L
Hensley
Eric
E
Mucker
Josh
J
Shamblin
Carly
C
Wlazlowski
Wendy
W
Johnson
Jennifer
J
Chapman
Tom
T
Larsen
Nancy
N
Twenhafel
Kevin
K
Karem
Inger K
IK
Damon
Chelsea M
CM
Byrd
Tove' C
TC
Bolken
Robert
R
Jordan
Dennis
D
Hruby
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000627:therapeutic use*; D008252:Macaca fascicularis; D008297:Male; D045908:Mpox, Monkeypox / Q000517:prevention & control*; D012899:Smallpox / Q000517:prevention & control*; D010797:Phthalimides
D000998:Antiviral Agents; D001549:Benzamides; D054833:Isoindoles; C505045:tecovirimat; D010797:Phthalimides